c4c held its first International Multi-Stakeholder Meeting (MSM) on paediatric Inflammatory Bowel Disease (IBD) virtually on 14-15 April 2021.
Over 100 individuals joined, representing patients and advocates, clinicians, academics, pharmaceutical companies, and regulators. The meeting was organised with the participation of the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).
The meeting aimed to propose a strategy to address the unmet needs of paediatric patients with IBD through science, prioritisation of paediatric compounds in development, introducing innovative development pathways and increasing accessibility for all patients.
More information about the event is available HERE.